Neon Therapeutics (NTGN) Sets New 1-Year Low at $6.17

Shares of Neon Therapeutics Inc (NASDAQ:NTGN) reached a new 52-week low on Tuesday . The stock traded as low as $6.17 and last traded at $7.22, with a volume of 7055 shares trading hands. The stock had previously closed at $7.18.

Several analysts recently weighed in on NTGN shares. Oppenheimer started coverage on Neon Therapeutics in a report on Monday, July 23rd. They issued a “$11.74” rating and a $20.00 price objective for the company. Bank of America started coverage on Neon Therapeutics in a report on Monday, July 23rd. They issued a “buy” rating and a $18.00 price objective for the company. Cann restated a “buy” rating and issued a $20.00 price objective on shares of Neon Therapeutics in a report on Tuesday, August 7th. Finally, Morgan Stanley started coverage on Neon Therapeutics in a report on Monday, July 23rd. They issued an “overweight” rating and a $23.00 price objective for the company.

Neon Therapeutics (NASDAQ:NTGN) last posted its earnings results on Monday, August 6th. The company reported ($7.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($7.04). research analysts forecast that Neon Therapeutics Inc will post -5.5 earnings per share for the current fiscal year.

In related news, major shareholder Access Industries Holdings Llc bought 315,000 shares of the business’s stock in a transaction on Friday, June 29th. The shares were bought at an average price of $16.00 per share, for a total transaction of $5,040,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

A number of institutional investors and hedge funds have recently bought and sold shares of NTGN. Point72 Hong Kong Ltd purchased a new position in Neon Therapeutics in the second quarter valued at about $105,000. Highland Capital Management LP purchased a new position in Neon Therapeutics in the second quarter valued at about $137,000. Northern Trust Corp purchased a new position in Neon Therapeutics in the second quarter valued at about $137,000. Bain Capital Public Equity Management LLC purchased a new position in Neon Therapeutics in the second quarter valued at about $147,000. Finally, Maso Capital Partners Ltd purchased a new stake in shares of Neon Therapeutics during the second quarter worth about $441,000. Institutional investors own 65.75% of the company’s stock.

About Neon Therapeutics (NASDAQ:NTGN)

Neon Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer.

Featured Story: Find a Trading Strategy That Works

Receive News & Ratings for Neon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply